Suppr超能文献

肝癌肝移植等待时间的利弊

Benefit and harm of waiting time in liver transplantation for HCC.

作者信息

van der Meeren Pam Elisabeth, de Wilde Roeland Frederik, Sprengers Dave, IJzermans Jan Nicolaas Maria

机构信息

Department of Surgery, Division of HPB & Transplant Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Department of Gastroenterology & Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.

出版信息

Hepatology. 2025 Jul 1;82(1):212-231. doi: 10.1097/HEP.0000000000000668. Epub 2025 Jun 19.

Abstract

Liver transplantation is the most successful treatment for limited-stage HCC. The waiting time for liver transplantation (LT) can be a critical factor affecting the oncological prognosis and outcome of patients with HCC. Efficient strategies to optimize waiting time are essential to maximize the benefits of LT and to reduce the harm of delay in transplantation. The ever-increasing demand for donor livers emphasizes the need to improve the organization of the waiting list for transplantation and to optimize organ availability for patients with and without HCC. Current progress in innovations to expand the donor pool includes the implementation of living donor LT and the use of grafts from extended donors. By expanding selection criteria, an increased number of patients are eligible for transplantation, which necessitates criteria to prevent futile transplantations. Thus, the selection criteria for LT have evolved to include not only tumor characteristics but biomarkers as well. Enhancing our understanding of HCC tumor biology through the analysis of subtypes and molecular genetics holds significant promise in advancing the personalized approach for patients. In this review, the effect of waiting time duration on outcome in patients with HCC enlisted for LT is discussed.

摘要

肝移植是局限性肝癌最成功的治疗方法。肝移植(LT)的等待时间可能是影响肝癌患者肿瘤学预后和结局的关键因素。优化等待时间的有效策略对于最大化肝移植的益处以及减少移植延迟的危害至关重要。对供肝的需求不断增加,这凸显了改善移植等待名单管理以及优化有或没有肝癌患者器官可及性的必要性。扩大供体库的创新举措目前取得的进展包括实施活体供体肝移植以及使用来自扩大标准供体的移植物。通过扩大选择标准,越来越多的患者符合移植条件,这就需要制定标准以防止无效移植。因此,肝移植的选择标准已经发展到不仅包括肿瘤特征,还包括生物标志物。通过分析亚型和分子遗传学加深我们对肝癌肿瘤生物学的理解,在推进针对患者的个性化治疗方法方面具有重大前景。在本综述中,讨论了等待时间对列入肝移植名单的肝癌患者结局的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验